
Opinion|Videos|October 15, 2024
Patient Profile 1: A 70-Year-Old Man With PSMA-Positive mCRPC
Author(s)Oliver Sartor, MD
Key Takeaways
Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential radioligand therapy, considering factors such as disease progression, previous treatments, and overall health status in tailoring management strategies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts discuss the challenge of detecting CIS in bladder cancer
2
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
3
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
4
Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation
5













